NBIX vs. MSFT

In the year-to-date period, NBIX achieves a -14.38% return, which is significantly lower than MSFT's -2.60% return. Over the past 10 years, NBIX has underperformed MSFT with an annualized return of 12.15%, while MSFT has yielded a comparatively higher 27.04% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Microsoft Corporation (MSFT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NBIX Sharpe Ratio is -0.28, which is lower than the MSFT Sharpe Ratio of -0.02. The chart below compares the historical Sharpe Ratios of NBIX and MSFT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

NBIX has not paid dividends to shareholders, while MSFT's dividend yield for the trailing twelve months is around 0.57%.

The maximum NBIX drawdown since its inception was -97.21%, which is greater than MSFT's maximum drawdown of -69.39%. Use the drawdown chart below to compare losses from any high point for NBIX and MSFT. For additional features, visit the drawdowns tool.

Neurocrine Biosciences, Inc. (NBIX) has a higher volatility of 21.49% compared to Microsoft Corporation (MSFT) at 9.38%. This indicates that NBIX's price experiences larger fluctuations and is considered to be riskier than MSFT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Microsoft Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.